Journal
GENE THERAPY
Volume -, Issue -, Pages -Publisher
SPRINGERNATURE
DOI: 10.1038/s41434-022-00376-9
Keywords
-
Categories
Funding
- Sao Paulo Research Foundation (FAPESP) [16/14358-2]
- Brazilian National Research Council (CNPq)
- Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [16/14358-2] Funding Source: FAPESP
Ask authors/readers for more resources
This study evaluated the potential of an anti-bevacizumab idiotype single-chain variable fragment (scFv) in a gene immunization strategy and found that it has the ability to induce an immune response containing VEGF-binding antibodies.
Anti-idiotype antibodies have been considered for vaccination approaches against different diseases, including cancers. Based on that, we previously described an anti-bevacizumab idiotype monoclonal antibody, 10.D7, that revealed detectable antitumor effects on a vascular endothelial growth factor (VEGF)-dependent tumor model. Herein, we evaluated the possible applicability of a single-chain variable fragment (scFv) for the 10.D7 antibody in a gene immunization strategy. After checking that mammalian cells transfected to express the 10.D7 scFv are recognized by bevacizumab, it was explored the ability of our scFv construction, in a gene-based scheme, to elicit an immune response containing VEGF-binding antibodies. The results provide evidence that the designed 10.D7 scFv construct maintains the anti-bevacizumab idiotype features and has potential to activate an immune response recognizing VEGF.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available